VLSI Tells Jury $3B Intel Case Hinges On Witness Credibility
Cara Salvatore, 20 April 2021
Patent holder VLSI made its final argument Tuesday that Intel owes $3 billion for allegedly infringing chip-voltage-regulation technology, telling a Texas federal jury Intel’s witnesses contradicted themselves at moments they weren’t “getting the script right.”
In the second of three planned trials in the multipatent case, hedge-fund-owned VLSI has argued that Intel chip properties directly echoed two technologies invented by engineers at a company called Sigmatel around the year 2000. The patents are U.S. Patent Number 6,633,187, which covers “waking up” chip cores very quickly from power-saving idle states, and U.S. Patent Number 6,366,522, which covers regulating power draw while the cores are awake. Continue reading “Article: VLSI Tells Jury $3B Intel Case Hinges On Witness Credibility”
5 Key Details As Drugmakers Face $50B Opioid Trial In Calif.
Jeff Overley, Cara Salvatore and Emily Field, 16 April 2021
Barring last-minute settlements, Johnson & Johnson, Endo Pharmaceuticals and other major drugmakers are poised to go to trial Monday against some of California’s largest counties, which are seeking $50 billion in one of the nation’s oldest opioid-crisis cases.
The West Coast clash centers on now-familiar allegations that pharmaceutical manufacturers — divisions of J&J, Endo, Teva Pharmaceuticals and Allergan PLC — to varying degrees bankrolled pernicious promotional campaigns for prescription painkillers, unleashing a devastating wave of drug dependence and death. Continue reading “Article: 5 Key Details As Drugmakers Face $50B Opioid Trial In Calif.”